FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230797592> ?p ?o ?g. }

• W4230797592 endingPage "4079" @default.
• W4230797592 startingPage "4079" @default.
• W4230797592 abstract "Abstract Abstract 4079 The treatment and natural history of asymptomatic or smoldering myeloma has been an area of intense preclinical and clinical study. Historical attempts to treat these patients have not demonstrated significant benefit, likely as a consequence of limited therapeutic options as well lack of attention to the vast heterogeneity contained within the diagnosis of smoldering myeloma. More recent risk criteria from both US and Spanish investigators have identified a cohort of smoldering myeloma patients at high risk for progression to myeloma in a short time. Recently the PETHEMA group has conducted a randomized clinical trial testing lenalidomide and dexamethasone vs observation among high risk smoldering patients and has demonstrated a clear benefit in terms of progression free survival and hints towards improvement in overall survival favoring early intervention. To further evaluate the potential benefit of early intervention in a high risk smoldering cohort, the ECOG myeloma group designed a phase II trial testing the safety and efficacy of single agent lenalidomide with the intent of broadening to a randomized phase III trial if toxicity was acceptable. We report here on the safety portion of the phase II trial. The phase II group of patients received lenalidomide at a dose of 25 mg days 1–21 every 28 days to evaluate the early toxicity and tolerance of this dosing. The dose of lenalidomide could be adjusted based on toxicity using a defined dose-modification guideline in the protocol. The primary endpoint for the safety study was the rate of any treatment-related grade 4–5 non-hematologic toxicity plus grade 3 non-hematologic toxicity that affects vital organ function (such as cardiac, hepatic, or thromboembolic events) observed within 6 cycles of treatment. The goal was to enroll 34 patients; if 9 or more patients experience toxicity as defined, then the study would not continue. In terms of eligibility, patients were to be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 12 months, as confirmed by both of the following: bone marrow plasmacytosis with >= 10% plasma cells or sheets of plasma cells and an abnormal serum free light chain ratio (<0.125 or >8.0) by serum FLC assay. Further, patients must have measurable levels of monoclonal protein (M-protein): >=1g/dL on serum protein electrophoresis or >=200 mg of monoclonal protein on a 24 hour urine protein electrophoresis. Patients must have no lytic lesions on skeletal surveys and no hypercalcemia. Among the 36 patients enrolled in the phase II study, 56% were female, and 44% were 65 years and older. Treatment and toxicity data at a minimum through cycle 6 is complete as of August 2, 2102. The last patient enrolled completed cycle 6 treatment on June 7, 2012. The median treatment duration of the entire cohort is 9 cycles (range 1–18 cycles), with 86% of patients completing at least 6 cycles of treatment. Ten patients are off treatment for the following reasons: disease progression (n=1), AE/complication (n=5), death (n=1) and patient withdrawal/refusal (n=3); 5 of the 10 patients ended treatment before completing 6 cycles. Of 36 patients assessed for toxicity, 8 patients [22.2%, 90% CI: (11.6%-36.5%)] experienced worst grade treatment-related non-hematologic toxicity of grade 3 or higher. Separately, 6 patients experienced unrelated non-hematologic toxicity of grade 3 or higher. Three patients [8.3%, 90% CI: (2.3%-20.2%)] experienced a serious adverse event as defined for the purposes of the phase II toxicity analysis (treatment-related grade 4–5 non-hematologic toxicity or grade 3 non-hematologic toxicity that affects vital organ function (such as cardiac, hepatic, or thromboembolic events). Based upon this analysis of the study, the phase II portion of the trial met the prespecified safety benchmark established to allow for phase III expansion, and accrual to the phase III portion of this study will begin. Efficacy data will be presented at the time of presentation. Disclosures: Lonial: Novartis: Consultancy; Millennium: Consultancy; Onyx: Consultancy; BMS: Consultancy; Celgene Corp: Consultancy; Merck: Consultancy. Off Label Use: Lenalidomide is not approved for treatment of smoldering MM. Fonseca:Medtronic: Consultancy; Otsuka: Consultancy; Celgene: Consultancy; Genzyme: Consultancy; BMS: Consultancy; Lilly: Consultancy; Onyx: Consultancy; Binding site: Consultancy; Millenium: Consultancy; AMGEN: Consultancy; Celgene : Research Funding; Onyx: Research Funding; prognostication of MM based on genetic categorization of the disease: Prognostication of MM based on genetic categorization of the disease, Prognostication of MM based on genetic categorization of the disease Patents & Royalties. Dhodapkar:Celgene: Research Funding; KHK: Research Funding." @default.
• W4230797592 created "2022-05-11" @default.
• W4230797592 creator A5002652857 @default.
• W4230797592 creator A5003015868 @default.
• W4230797592 creator A5023276777 @default.
• W4230797592 creator A5054957898 @default.
• W4230797592 creator A5064175914 @default.
• W4230797592 creator A5088696429 @default.
• W4230797592 date "2012-11-16" @default.
• W4230797592 modified "2023-09-26" @default.
• W4230797592 title "Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group" @default.
• W4230797592 doi "https://doi.org/10.1182/blood.v120.21.4079.4079" @default.
• W4230797592 hasPublicationYear "2012" @default.
• W4230797592 type Work @default.
• W4230797592 citedByCount "1" @default.
• W4230797592 countsByYear W42307975922019 @default.
• W4230797592 crossrefType "journal-article" @default.
• W4230797592 hasAuthorship W4230797592A5002652857 @default.
• W4230797592 hasAuthorship W4230797592A5003015868 @default.
• W4230797592 hasAuthorship W4230797592A5023276777 @default.
• W4230797592 hasAuthorship W4230797592A5054957898 @default.
• W4230797592 hasAuthorship W4230797592A5064175914 @default.
• W4230797592 hasAuthorship W4230797592A5088696429 @default.
• W4230797592 hasConcept C126322002 @default.
• W4230797592 hasConcept C141071460 @default.
• W4230797592 hasConcept C143998085 @default.
• W4230797592 hasConcept C168563851 @default.
• W4230797592 hasConcept C203092338 @default.
• W4230797592 hasConcept C2776063141 @default.
• W4230797592 hasConcept C2776364478 @default.
• W4230797592 hasConcept C2778524551 @default.
• W4230797592 hasConcept C31760486 @default.
• W4230797592 hasConcept C535046627 @default.
• W4230797592 hasConcept C71924100 @default.
• W4230797592 hasConcept C72563966 @default.
• W4230797592 hasConcept C73751289 @default.
• W4230797592 hasConceptScore W4230797592C126322002 @default.
• W4230797592 hasConceptScore W4230797592C141071460 @default.
• W4230797592 hasConceptScore W4230797592C143998085 @default.
• W4230797592 hasConceptScore W4230797592C168563851 @default.
• W4230797592 hasConceptScore W4230797592C203092338 @default.
• W4230797592 hasConceptScore W4230797592C2776063141 @default.
• W4230797592 hasConceptScore W4230797592C2776364478 @default.
• W4230797592 hasConceptScore W4230797592C2778524551 @default.
• W4230797592 hasConceptScore W4230797592C31760486 @default.
• W4230797592 hasConceptScore W4230797592C535046627 @default.
• W4230797592 hasConceptScore W4230797592C71924100 @default.
• W4230797592 hasConceptScore W4230797592C72563966 @default.
• W4230797592 hasConceptScore W4230797592C73751289 @default.
• W4230797592 hasIssue "21" @default.
• W4230797592 hasLocation W42307975921 @default.
• W4230797592 hasOpenAccess W4230797592 @default.
• W4230797592 hasPrimaryLocation W42307975921 @default.
• W4230797592 hasRelatedWork W12229326 @default.
• W4230797592 hasRelatedWork W12291014 @default.
• W4230797592 hasRelatedWork W14105614 @default.
• W4230797592 hasRelatedWork W18275474 @default.
• W4230797592 hasRelatedWork W19039903 @default.
• W4230797592 hasRelatedWork W2727520 @default.
• W4230797592 hasRelatedWork W8713393 @default.
• W4230797592 hasRelatedWork W8870890 @default.
• W4230797592 hasRelatedWork W9899198 @default.
• W4230797592 hasRelatedWork W17299077 @default.
• W4230797592 hasVolume "120" @default.
• W4230797592 isParatext "false" @default.
• W4230797592 isRetracted "false" @default.
• W4230797592 workType "article" @default.